Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.650,05 +21,57 (+0,06%) EUR/USD
1,0730 -0,0003 (-0,03%) Bitcoin EUR
59.960,68 -218,11 (-0,36%) CMC Crypto 200
1.390,69 +8,12 (+0,59%)
CRISPR Therapeutics AG (CRSP)
Dopo ore:
| Chiusura precedente | 55,65 |
| Aperto | 54,00 |
| Denaro | 53,72 x 200 |
| Lettera | 53,79 x 200 |
| Min-Max giorno | 52,75 - 54,15 |
| Intervallo di 52 settimane | 37,55 - 91,10 |
| Volume | |
| Media Volume | 1.739.693 |
| Capitalizzazione | 4,724B |
| Beta (5 anni mensile) | 1,74 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,88 |
| Prossima data utili | 21 feb 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 85,88 |
GlobeNewswireCRISPR Therapeutics Proposes New Appointment to the Board of Directors
ZUG, Switzerland and BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Sandy Mahatme, LL.M. to its Board of Directors at the Company’s next annual general meeting to be held in 2024. “I am honored to welcome Sandy to our Board during an important time in CRISPR Therapeutics’ continued evolution,” said Samarth Kulkarni, Ph.D., C
- GlobeNewswire
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023. Title: Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CAR T cell
- GlobeNewswire
CRISPR Therapeutics Announces Leadership Transition
-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023--Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue serving as CEO of the Company- ZUG, Switzerland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Rodger Novak, M.D., President and Chairman
